Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) announced that 90% of patients in its Phase 2b clinical trial of RAD 101 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE